These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

547 related items for PubMed ID: 18814813

  • 1. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ, Hammett J, Malcolm JB, Judge BA, Womack JH, Kincade MC, Ogles ML, Mancini JG, Patterson AL, Wake RW, Derweesh IH.
    Can J Urol; 2008 Oct; 15(5):4249-56; discussion 4256. PubMed ID: 18814813
    [Abstract] [Full Text] [Related]

  • 2. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ, Malcolm JB, Derweesh IH, Womack JH, Kincade MC, Mancini JG, Ogles ML, Lamar KD, Patterson AL, Wake RW.
    BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
    [Abstract] [Full Text] [Related]

  • 3. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB, Derweesh IH, Kincade MC, DiBlasio CJ, Lamar KD, Wake RW, Patterson AL.
    Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
    [Abstract] [Full Text] [Related]

  • 4. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ, Malcolm JB, Hammett J, Wan JY, Aleman MA, Patterson AL, Wake RW, Derweesh IH.
    BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK.
    Cancer; 2008 Mar 15; 112(6):1247-53. PubMed ID: 18293426
    [Abstract] [Full Text] [Related]

  • 6. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]

  • 7. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    Janoff DM, Peterson C, Mongoue-Tchokote S, Peters L, Beer TM, Wersinger EM, Mori M, Garzotto M.
    BJU Int; 2005 Sep 15; 96(4):503-7. PubMed ID: 16104900
    [Abstract] [Full Text] [Related]

  • 8. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ.
    Urology; 2004 Aug 15; 64(2):335-40. PubMed ID: 15302490
    [Abstract] [Full Text] [Related]

  • 9. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study.
    Pirl WF, Siegel GI, Goode MJ, Smith MR.
    Psychooncology; 2002 Aug 15; 11(6):518-23. PubMed ID: 12476433
    [Abstract] [Full Text] [Related]

  • 10. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Efstathiou JA, Skowronski RY, Coen JJ, Grocela JA, Hirsch AE, Zietman AL.
    Int J Radiat Oncol Biol Phys; 2008 Aug 01; 71(5):1302-8. PubMed ID: 18262732
    [Abstract] [Full Text] [Related]

  • 11. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA.
    Cancer; 2009 Oct 01; 115(19):4470-6. PubMed ID: 19637339
    [Abstract] [Full Text] [Related]

  • 12. Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE.
    Aaronson D, Cowan J, Carroll P, Konety B.
    BJU Int; 2010 Apr 01; 105(7):951-5. PubMed ID: 19889066
    [Abstract] [Full Text] [Related]

  • 13. Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy.
    Saini A, Berruti A, Cracco C, Sguazzotti E, Porpiglia F, Russo L, Bertaglia V, Picci RL, Negro M, Tosco A, Campagna S, Scarpa RM, Dogliotti L, Furlan PM, Ostacoli L.
    Urol Oncol; 2013 Apr 01; 31(3):352-8. PubMed ID: 21803612
    [Abstract] [Full Text] [Related]

  • 14. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
    Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S.
    J Clin Oncol; 2006 Aug 20; 24(24):3979-83. PubMed ID: 16921050
    [Abstract] [Full Text] [Related]

  • 15. Rising prostate-specific antigen values during neoadjuvant androgen deprivation therapy: The importance of monitoring.
    Niblock P, Pickles T, British Columbia Cancer Agency Prostate Cohort Outcomes Initiative.
    Int J Radiat Oncol Biol Phys; 2006 May 01; 65(1):59-64. PubMed ID: 16413696
    [Abstract] [Full Text] [Related]

  • 16. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.
    Ann Pharmacother; 2006 Dec 01; 40(12):2107-14. PubMed ID: 17132807
    [Abstract] [Full Text] [Related]

  • 17. Adverse effects of androgen deprivation therapy on persistent genitourinary complications after carbon ion radiotherapy for prostate cancer.
    Ishikawa H, Tsuji H, Kamada T, Hirasawa N, Yanagi T, Mizoe JE, Akakura K, Suzuki H, Shimazaki J, Nakano T, Tsujii H.
    Int J Radiat Oncol Biol Phys; 2008 Sep 01; 72(1):78-84. PubMed ID: 18456419
    [Abstract] [Full Text] [Related]

  • 18. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.
    J Natl Cancer Inst; 2007 Oct 17; 99(20):1516-24. PubMed ID: 17925537
    [Abstract] [Full Text] [Related]

  • 19. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
    Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q, Botteman M, Litwin MS.
    Cancer; 2004 Aug 01; 101(3):541-9. PubMed ID: 15274067
    [Abstract] [Full Text] [Related]

  • 20. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.
    Liauw SL, Fricano J, Correa D, Weichselbaum RR, Jani AB.
    Cancer; 2009 Apr 15; 115(8):1784-90. PubMed ID: 19208426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.